Literature DB >> 11134902

Amyloid-beta is an antioxidant for lipoproteins in cerebrospinal fluid and plasma.

A Kontush1, C Berndt, W Weber, V Akopyan, S Arlt, S Schippling, U Beisiegel.   

Abstract

Amyloid-beta (Abeta) peptide, a major constituent of senile plaques and a hallmark of Alzheimer's disease (AD), is normally secreted by neurons and can be found in low concentrations in cerebrospinal fluid (CSF) and plasma, where it is associated with lipoproteins. However, the physiological role of Abeta secretion remains unknown. Here we show that at the concentrations measured in biological fluids (0.1-1.0 nM), Abeta(1-40) strongly inhibits autooxidation of CSF lipoproteins and plasma low density lipoprotein (LDL). At higher concentrations of the peptide its antioxidant action was abolished. Abeta(1-40) also inhibited copper-catalyzed LDL oxidation when added in molar excess of copper, but did not influence oxidation induced by an azo-initiator. Other Abeta peptides also possessed antioxidant activity in the order Abeta(1-40) > Abeta(1-42) > Abeta(25-35), whereas Abeta(35-25) was inactive. These data suggest that Abeta(1-40) may act as a physiological antioxidant in CSF and plasma lipoproteins, functioning by chelating transition metal ions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11134902     DOI: 10.1016/s0891-5849(00)00458-5

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  48 in total

1.  Copper, beta-amyloid, and Alzheimer's disease: tapping a sensitive connection.

Authors:  Ashley I Bush; Colin L Masters; Rudolph E Tanzi
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-23       Impact factor: 11.205

Review 2.  Amyloid-β peptide: Dr. Jekyll or Mr. Hyde?

Authors:  Daniela Puzzo; Ottavio Arancio
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

Review 3.  Pathological implications of cell cycle re-entry in Alzheimer disease.

Authors:  David J Bonda; Hyun-pil Lee; Wataru Kudo; Xiongwei Zhu; Mark A Smith; Hyoung-gon Lee
Journal:  Expert Rev Mol Med       Date:  2010-06-29       Impact factor: 5.600

4.  Promotion of oxidative lipid membrane damage by amyloid beta proteins.

Authors:  Ian V J Murray; Michael E Sindoni; Paul H Axelsen
Journal:  Biochemistry       Date:  2005-09-20       Impact factor: 3.162

Review 5.  Oxidative imbalance in Alzheimer's disease.

Authors:  Xiongwei Zhu; Hyoung-Gon Lee; Gemma Casadesus; Jesus Avila; Kelly Drew; George Perry; Mark A Smith
Journal:  Mol Neurobiol       Date:  2005       Impact factor: 5.590

Review 6.  Novel therapeutics for Alzheimer's disease: an update.

Authors:  David J Bonda; Hyun-Pil Lee; Hyoung-gon Lee; Avi L Friedlich; George Perry; Xiongwei Zhu; Mark A Smith
Journal:  Curr Opin Drug Discov Devel       Date:  2010-03

7.  Defragmentation of lysozyme derived Amyloid β fibril using Biocompatible Magnetic fluid.

Authors:  Nidhi P Parikh; Kinnari H Parekh
Journal:  J Mater Sci Mater Med       Date:  2018-11-03       Impact factor: 3.896

Review 8.  The Ubiquitin-Proteasome System and Molecular Chaperone Deregulation in Alzheimer's Disease.

Authors:  Yanuar Alan Sulistio; Klaus Heese
Journal:  Mol Neurobiol       Date:  2015-01-07       Impact factor: 5.590

Review 9.  Oxidative stress signaling in Alzheimer's disease.

Authors:  B Su; X Wang; A Nunomura; P I Moreira; H-gon Lee; G Perry; M A Smith; X Zhu
Journal:  Curr Alzheimer Res       Date:  2008-12       Impact factor: 3.498

Review 10.  Review: cell cycle aberrations and neurodegeneration.

Authors:  D J Bonda; V P Bajić; B Spremo-Potparevic; G Casadesus; X Zhu; M A Smith; H-G Lee
Journal:  Neuropathol Appl Neurobiol       Date:  2010-01-06       Impact factor: 8.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.